Patient characteristics
| Patient no. . | Year of birth/sex . | Diagnosis . | Date of SCT . | Conditioning regimen . | Stem cell source . | Donor . | Sex mismatch . | HLA mismatch . | Chimerism . | ILT5 reactivity . | Titer . | Relapse . | GVHD . | DLI (reason) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H47 | 1978/M | CML chronic phase | October 2000 | Myeloablative | PSC | MSD | No | No | 100% d | v1 | 1:2000 | + June 2004 | No | Yes (relapse) |
| G96 | 1963/F | CML Ph+ | October 2003 | Myeloablative | PSC | MUD | No | Yes | 100% d | v1 | 1:20 000 | + (January 2006) | Yes | — |
| G189 | 1978/F | AML M4Eo | January 2005 | Myeloablative | PSC | MUD | Unknown | No | 100% d | v1 | 1:200 000 | + (December 2006) | Yes | — |
| G498 | 1981/M | Hodgkin relapse | August 2007 | Reduced | PSC | MSD | Yes | No | > 95% d | v1 | 1:2000 | — | Yes | December 2007 (mixed chimerism) |
| G38 | 1954/M | CML Ph+ | July 1996 | Myeloablative | BM | MUD | No | No | > 95% d | v1 | 1:6000 | — | Yes | — |
| G62 | 1972/F | AML M6a HR | January 2005 | Myeloablative | PSC | MSD | No | No | > 95% d | v1 | 1:200 000 | — | Yes | — |
| G486 | 1977/F | ALL | July 2007 | Myeloablative | PSC | MUD | Yes | No | 100% d | vt | 1:200 000 | — | Yes | — |
| G419 | 1987/M | T-ALL | April 2007 | Myeloablative | PSC | MSD | No | No | 100% d | v1 | 1:200 000 | — | No | — |
| G106 | 1965/F | CML Ph+ | January 2001 | Myeloablative | BM | MSD | No | No | 100% d | v1 | 1:600 000 | — | No | — |
| G260 | 1968/M | AML M2 | February 2004 | Myeloablative | PSC | MUD | No | No | 100% d | v1 | 1:6 000 000 | — | Yes | — |
| G401 | 1959/M | ALL-HR | March 2007 | Myeloablative | PSC | MUD | No | No | 100% d | v1 | 1:6 000 000 | — | Yes | — |
| G537 | 1976/M | c-ALL Ph+ | April 2007 | Myeloablative | PSC | MSD | Yes | No | > 95% d | v2 | 1:20 000 | — | Yes | — |
| G21 | 1941/F | NHL t14118 relapse | August 2003 | Reduced | PSC | MUD | Yes | No | 100% d | v2 | 1:60 000 | — | Yes | — |
| Patient no. . | Year of birth/sex . | Diagnosis . | Date of SCT . | Conditioning regimen . | Stem cell source . | Donor . | Sex mismatch . | HLA mismatch . | Chimerism . | ILT5 reactivity . | Titer . | Relapse . | GVHD . | DLI (reason) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H47 | 1978/M | CML chronic phase | October 2000 | Myeloablative | PSC | MSD | No | No | 100% d | v1 | 1:2000 | + June 2004 | No | Yes (relapse) |
| G96 | 1963/F | CML Ph+ | October 2003 | Myeloablative | PSC | MUD | No | Yes | 100% d | v1 | 1:20 000 | + (January 2006) | Yes | — |
| G189 | 1978/F | AML M4Eo | January 2005 | Myeloablative | PSC | MUD | Unknown | No | 100% d | v1 | 1:200 000 | + (December 2006) | Yes | — |
| G498 | 1981/M | Hodgkin relapse | August 2007 | Reduced | PSC | MSD | Yes | No | > 95% d | v1 | 1:2000 | — | Yes | December 2007 (mixed chimerism) |
| G38 | 1954/M | CML Ph+ | July 1996 | Myeloablative | BM | MUD | No | No | > 95% d | v1 | 1:6000 | — | Yes | — |
| G62 | 1972/F | AML M6a HR | January 2005 | Myeloablative | PSC | MSD | No | No | > 95% d | v1 | 1:200 000 | — | Yes | — |
| G486 | 1977/F | ALL | July 2007 | Myeloablative | PSC | MUD | Yes | No | 100% d | vt | 1:200 000 | — | Yes | — |
| G419 | 1987/M | T-ALL | April 2007 | Myeloablative | PSC | MSD | No | No | 100% d | v1 | 1:200 000 | — | No | — |
| G106 | 1965/F | CML Ph+ | January 2001 | Myeloablative | BM | MSD | No | No | 100% d | v1 | 1:600 000 | — | No | — |
| G260 | 1968/M | AML M2 | February 2004 | Myeloablative | PSC | MUD | No | No | 100% d | v1 | 1:6 000 000 | — | Yes | — |
| G401 | 1959/M | ALL-HR | March 2007 | Myeloablative | PSC | MUD | No | No | 100% d | v1 | 1:6 000 000 | — | Yes | — |
| G537 | 1976/M | c-ALL Ph+ | April 2007 | Myeloablative | PSC | MSD | Yes | No | > 95% d | v2 | 1:20 000 | — | Yes | — |
| G21 | 1941/F | NHL t14118 relapse | August 2003 | Reduced | PSC | MUD | Yes | No | 100% d | v2 | 1:60 000 | — | Yes | — |
ILT5 indicates immunoglobulin-like transcript 5; DLI, donor lymphocyte infusion; NHL, non-Hodgkin lymphoma; CML, chronic myeloid leukemia; AML acute myeloid leukemia; HR, high-risk; c-ALL, CALLA-positive acute lymphocytic leukemia; T-ALL, acute T-cell leukemia; PSC, peripheral stem cells; BM, bone marrow; MSD, matched sibling donor; MUD, matched unrelated donor; —, not applicable.